Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)

Genomic Profile and Tumor Immune Attack in Paraneoplastic Neurological Syndromes (PNS)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03963700

Acronym

GenePNS

Enrollment

980

Registered

2019-05-28

Start date

2019-02-01

Completion date

2022-01-01

Last updated

2019-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Immune System and Related Disorders, Neurologic Disorder, Paraneoplastic Syndromes, Tumor Genetics

Brief summary

Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that can affect any part of the central or peripheral nervous system. PNS occurs at the intersection between immune system and the tumor, where a combination of genetical and environmental factors may play a role. Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover, a better understanding of the biological mechanisms underlying PNS would allow a more precise identification of the modalities that permit PNS patients to have a better oncological prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology. To this effect, an extremely innovative approach involves directly exploring the tumoral tissue of patients suffering from specific PNS via genomic and transcriptomic analysis. The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to the generation of PNS. In the present study, the investigators will analyze the salient features of tumors associated with PNS, namely the histological and immune cells infiltrate characteristics, their transcriptomic profile, and mutational status of involved antigens.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* presence of well characterized antibodies in serum or cerebrospinal fluid; * histologically proven cancer with available tumour sample; * Paraneoplastic neurological syndrome (PNS) diagnosis according to the international guidelines; * Age: at least 18 years old.

Exclusion criteria

* Absence of complete clinicopathological data

Design outcomes

Primary

Measure	Time frame	Description
Proportion of mutations in cancer genes coding for onconeural proteins and inflammatory response mediators.	36 months	Genetic alterations in tumors associated with Paraneoplastic neurological syndromes (PNS)

Secondary

Measure	Time frame	Description
Proportion of different immune cells in the tumor's immune infiltrate	36 months	Histological immune infiltrate characteristics

Countries

France

Outcome results